JP2003529317A5 - - Google Patents

Download PDF

Info

Publication number: JP2003529317A5
Authority: JP; Japan
Prior art keywords: seq; approximately; sequence; pro866; pcr primer
Prior art date: 1999-12-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2000589692A

Other languages

English (en)

Japanese (ja)

Other versions

JP3993746B2 (ja

JP2003529317A (ja

Filing date

1999-12-02

Publication date

2004-12-24

1999-03-08 Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/fr

1999-09-15 Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/fr

1999-09-15 Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/fr

1999-12-02 Application filed filed Critical

1999-12-02 Priority claimed from PCT/US1999/028565 external-priority patent/WO2000037638A2/fr

2003-10-07 Publication of JP2003529317A publication Critical patent/JP2003529317A/ja

2004-12-24 Publication of JP2003529317A5 publication Critical patent/JP2003529317A5/ja

2007-10-17 Application granted granted Critical

2007-10-17 Publication of JP3993746B2 publication Critical patent/JP3993746B2/ja

2019-12-02 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

150000001413 amino acids Chemical class 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
239000000523 sample Substances 0.000 description 4
108091035707 Consensus sequence Proteins 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
102100036427 Spondin-2 Human genes 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
108010074865 mindin Proteins 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 description 1

JP2000589692A 1998-12-22 1999-12-02 腫瘍性細胞成長阻害のための組成物及び方法 Expired - Fee Related JP3993746B2 (ja)

Applications Claiming Priority (19)

Application Number	Priority Date	Filing Date	Title
US11329698P	1998-12-22	1998-12-22
US60/113,296		1998-12-22
PCT/US1999/005028 WO1999046281A2 (fr)	1998-03-10	1999-03-08	Nouveaux polypeptides et acides nucleiques les codant
US9905028		1999-03-08
US13023299P	1999-04-21	1999-04-21
US60/130,232		1999-04-21
US13144599P	1999-04-28	1999-04-28
US60/131,445		1999-04-28
US13428799P	1999-05-14	1999-05-14
US60/134,287		1999-05-14
US14475899P	1999-07-20	1999-07-20
US60/144,758		1999-07-20
US14569899P	1999-07-26	1999-07-26
US60/145,698		1999-07-26
PCT/US1999/021547 WO2000015797A2 (fr)	1998-09-17	1999-09-15	Compositions et methodes de traitement des maladies relatives au syteme immunitaire
US9921547		1999-09-15
PCT/US1999/021090 WO2000015796A2 (fr)	1998-09-16	1999-09-15	Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US9921090		1999-09-15
PCT/US1999/028565 WO2000037638A2 (fr)	1998-12-22	1999-12-02	Methodes permettant d'inhiber la croissance de cellules neoplasiques

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2005066570A Division JP2005237383A (ja)	1998-12-22	2005-03-10	腫瘍性細胞成長阻害のための組成物及び方法
JP2005066569A Division JP4037876B2 (ja)	1998-12-22	2005-03-10	腫瘍性細胞成長阻害のための組成物及び方法

Publications (3)

Publication Number	Publication Date
JP2003529317A JP2003529317A (ja)	2003-10-07
JP2003529317A5 true JP2003529317A5 (fr)	2004-12-24
JP3993746B2 JP3993746B2 (ja)	2007-10-17

Family

ID=27557838

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
JP2000589692A Expired - Fee Related JP3993746B2 (ja)	1998-12-22	1999-12-02	腫瘍性細胞成長阻害のための組成物及び方法
JP2005066569A Expired - Lifetime JP4037876B2 (ja)	1998-12-22	2005-03-10	腫瘍性細胞成長阻害のための組成物及び方法
JP2005066570A Withdrawn JP2005237383A (ja)	1998-12-22	2005-03-10	腫瘍性細胞成長阻害のための組成物及び方法
JP2007138469A Pending JP2007291116A (ja)	1998-12-22	2007-05-24	腫瘍性細胞成長阻害のための組成物及び方法
JP2007138468A Pending JP2007222180A (ja)	1998-12-22	2007-05-24	腫瘍性細胞成長阻害のための組成物及び方法

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
JP2005066569A Expired - Lifetime JP4037876B2 (ja)	1998-12-22	2005-03-10	腫瘍性細胞成長阻害のための組成物及び方法
JP2005066570A Withdrawn JP2005237383A (ja)	1998-12-22	2005-03-10	腫瘍性細胞成長阻害のための組成物及び方法
JP2007138469A Pending JP2007291116A (ja)	1998-12-22	2007-05-24	腫瘍性細胞成長阻害のための組成物及び方法
JP2007138468A Pending JP2007222180A (ja)	1998-12-22	2007-05-24	腫瘍性細胞成長阻害のための組成物及び方法

Country Status (13)

Country	Link
EP (1)	EP1141284A2 (fr)
JP (5)	JP3993746B2 (fr)
KR (1)	KR100499600B1 (fr)
AT (2)	ATE432987T1 (fr)
AU (1)	AU768230B2 (fr)
CA (1)	CA2353799A1 (fr)
DE (2)	DE69940964D1 (fr)
DK (1)	DK1484338T3 (fr)
ES (2)	ES2281704T3 (fr)
IL (3)	IL143031A0 (fr)
MX (1)	MXPA01006330A (fr)
PT (1)	PT1484338E (fr)
WO (1)	WO2000037638A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000053757A2 (fr) *	1999-03-08	2000-09-14	Genentech, Inc.	Activation et inhibition de l'angiogenese et de la cardiovascularisation
US6392019B1 (en)	1997-11-22	2002-05-21	John Ford	Antibodies specific for EGF motif proteins
US6808890B2 (en)	1999-07-28	2004-10-26	Nuvelo, Inc.	Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US7419663B2 (en)	1998-03-20	2008-09-02	Genentech, Inc.	Treatment of complement-associated disorders
US7192589B2 (en)	1998-09-16	2007-03-20	Genentech, Inc.	Treatment of inflammatory disorders with STIgMA immunoadhesins
US8007798B2 (en)	1997-11-21	2011-08-30	Genentech, Inc.	Treatment of complement-associated disorders
US8088386B2 (en)	1998-03-20	2012-01-03	Genentech, Inc.	Treatment of complement-associated disorders
AU763012B2 (en)	1997-11-22	2003-07-10	Arca Biopharma, Inc.	A novel EGF motif protein obtained from a cDNA library of fetal liver-spleen
EP1251139A3 (fr) *	1998-04-08	2002-12-18	Genentech, Inc.	Protéine semblable à mendin humain et acides nucléiques le codant
CA2331154A1 (fr)	1998-06-16	1999-12-23	Human Genome Sciences, Inc.	Polypeptides presentant une sequence distincte comprenant une sous-unite de facteur de croissance insulinomimetique labile en milieu acide
US6960433B1 (en)	1998-10-19	2005-11-01	Diadexus, Inc.	Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
CN1387538A (zh)	1999-01-15	2002-12-25	比奥根公司	针对tweak及tweak受体的拮抗剂和它们在治疗免疫性疾病中的应用
JP2003505350A (ja) *	1999-07-20	2003-02-12	ジェネンテック・インコーポレーテッド	免疫関連疾患の治療のための組成物と方法
KR20020062652A (ko) *	1999-12-09	2002-07-26	상꾜 가부시키가이샤	고지혈증의 치료 또는 예방제의 시험방법
US7119165B2 (en)	2000-01-12	2006-10-10	Yale University	Nogo receptor-mediated blockade of axonal growth
NZ520065A (en) *	2000-01-12	2006-02-24	Univ Yale	Nogo receptor-mediated blockade of axonal growth
JP2004500844A (ja)	2000-05-08	2004-01-15	バイオジェン　インコーポレイテッド	Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7208151B2 (en)	2001-09-12	2007-04-24	Biogen Idec Ma Inc.	Tweak receptor agonists as anti-angiogenic agents
DE60141409D1 (de)	2000-10-06	2010-04-08	Biogen Idec Inc	Homologe des nogo rezeptors
US20020111302A1 (en) *	2000-11-30	2002-08-15	Y. Tom Tang	Novel nucleic acids and polypeptides
IL164352A0 (en)	2002-04-09	2005-12-18	Biogen Idec Inc	Methods for treating tweak-related conditions
CA2391438A1 (fr) *	2002-05-01	2003-11-01	Procyon Biopharma Inc.	Reactifs et methodes diagnostiques a base de psp94
US7294704B2 (en)	2003-08-15	2007-11-13	Diadexus, Inc.	Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
WO2006089095A2 (fr)	2005-02-17	2006-08-24	Biogen Idec Ma Inc.	Traitement de troubles neurologiques
ES2432564T3 (es)	2005-05-10	2013-12-04	Biogen Idec Ma Inc.	Tratamiento y evaluación de trastornos inflamatorios
WO2006138219A2 (fr)	2005-06-13	2006-12-28	Biogen Idec Ma Inc.	Procedes d'evaluation de patients
WO2007008732A2 (fr)	2005-07-07	2007-01-18	Yale University	Compositions et procedes pour supprimer l'inhibition de la croissance axonale
UA99591C2 (ru)	2005-11-04	2012-09-10	Дженентек, Инк.	Применение ингибиторов пути комплемента для лечения глазных болезней
WO2007117657A2 (fr)	2006-04-07	2007-10-18	The Research Foundation Of State University Of New York	Polypeptides du récepteur de la transcobalamine, acides nucléiques et modulateurs associés, procédés d'utilisation associés destinés à moduler la croissance cellulaire et à traiter le cancer et la déficience en cobalamine
US9044461B2 (en)	2006-04-07	2015-06-02	The Research Foundation Of State University Of New York	Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7776573B2 (en)	2006-06-01	2010-08-17	Genentech, Inc.	Crystal structure of CRIg and C3b:CRIg complex
NZ576812A (en)	2006-11-02	2011-11-25	Genentech Inc	Humanized anti-factor d antibodies
AR066660A1 (es)	2007-05-23	2009-09-02	Genentech Inc	Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es)	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
CL2009001083A1 (es)	2008-05-06	2011-01-07	Genentech Inc	Variantes de receptores de la proteina c3 de complemento (crig), molecula quimerica y composicion farmaceutica que las comprende; uso de las variantes para preparar un medicamento para prevenir o tratar una enfermedad asociada al complemento, tal como una enfermedad inflamatoria o autoinmune.
US9120858B2 (en)	2011-07-22	2015-09-01	The Research Foundation Of State University Of New York	Antibodies to the B12-transcobalamin receptor
PE20160192A1 (es)	2013-08-12	2016-04-27	Genentech Inc	Composiciones y metodo para tratar condiciones asociadas con el complemento
JP2017515811A (ja)	2014-05-01	2017-06-15	ジェネンテック，インコーポレイテッド	抗ｄ因子抗体変異体及びその使用法
US10654932B2 (en)	2015-10-30	2020-05-19	Genentech, Inc.	Anti-factor D antibody variant conjugates and uses thereof
CN108289951A (zh)	2015-10-30	2018-07-17	豪夫迈·罗氏有限公司	抗-因子d抗体和缀合物
CN114835774B (zh) *	2022-06-29	2022-09-27	中国农业大学	辣椒籽分离的寡肽msl及其在预防或治疗癌症中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ226799A (en) *	1987-11-06	1991-08-27	Oncogen	Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) *	1989-04-10	1998-09-29	Bristol-Myers Squibb Company	Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) *	1990-04-03	1995-05-16	Bristol-Myers Squibb Company	Epithelins: novel cysteine-rich growth modulating proteins
US5028099A (en) *	1990-08-08	1991-07-02	Bertucco Leonard J	Trash recycling container
US6030831A (en) *	1997-09-19	2000-02-29	Genetech, Inc.	Tie ligand homologues
AU3661199A (en) *	1998-04-27	1999-11-16	Zymogenetics Inc.	Novel polypeptide growth factors and materials and methods for making them
SV1999000069A (es) *	1998-06-02	2000-04-11	Lilly Co Eli	Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
JP7039446B2 (ja) *	2018-11-29	2022-03-22	株式会社東芝	電子装置

1999
- 1999-12-02 WO PCT/US1999/028565 patent/WO2000037638A2/fr not_active Ceased
- 1999-12-02 ES ES04007617T patent/ES2281704T3/es not_active Expired - Lifetime
- 1999-12-02 DE DE69940964T patent/DE69940964D1/de not_active Expired - Lifetime
- 1999-12-02 AT AT07001711T patent/ATE432987T1/de not_active IP Right Cessation
- 1999-12-02 KR KR10-2001-7007850A patent/KR100499600B1/ko not_active Expired - Fee Related
- 1999-12-02 AT AT04007617T patent/ATE353339T1/de active
- 1999-12-02 ES ES07001711T patent/ES2327785T3/es not_active Expired - Lifetime
- 1999-12-02 AU AU17499/00A patent/AU768230B2/en not_active Expired
- 1999-12-02 DK DK04007617T patent/DK1484338T3/da active
- 1999-12-02 PT PT04007617T patent/PT1484338E/pt unknown
- 1999-12-02 IL IL14303199A patent/IL143031A0/xx not_active IP Right Cessation
- 1999-12-02 MX MXPA01006330A patent/MXPA01006330A/es not_active Application Discontinuation
- 1999-12-02 EP EP99960644A patent/EP1141284A2/fr not_active Withdrawn
- 1999-12-02 JP JP2000589692A patent/JP3993746B2/ja not_active Expired - Fee Related
- 1999-12-02 CA CA002353799A patent/CA2353799A1/fr not_active Abandoned
- 1999-12-02 DE DE69935085T patent/DE69935085T2/de not_active Expired - Lifetime
2005
- 2005-03-10 JP JP2005066569A patent/JP4037876B2/ja not_active Expired - Lifetime
- 2005-03-10 JP JP2005066570A patent/JP2005237383A/ja not_active Withdrawn
2007
- 2007-05-24 JP JP2007138469A patent/JP2007291116A/ja active Pending
- 2007-05-24 JP JP2007138468A patent/JP2007222180A/ja active Pending
- 2007-09-20 IL IL186153A patent/IL186153A0/en unknown
- 2007-09-20 IL IL186154A patent/IL186154A0/en unknown

Publication	Publication Date	Title
JP2003529317A5 (fr)	2004-12-24
JP2003524387A5 (fr)	2004-12-24
Kalikin et al.	2000	Genomic and expression analyses of alternatively spliced transcripts of the MLL septin-like fusion gene (MSF) that map to a 17q25 region of loss in breast and ovarian tumors
JP2004522402A5 (fr)	2004-12-24
Nomura et al.	1994	Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1
Mink et al.	2001	A novel human gene (SARM) at chromosome 17q11 encodes a protein with a SAM motif and structural similarity to Armadillo/β-catenin that is conserved in mouse, Drosophila, and Caenorhabditis elegans
Lin et al.	2001	Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B
Nakata et al.	1999	Fusion of a novel gene, ELKS, to RET due to translocation t (10; 12)(q11; p13) in a papillary thyroid carcinoma
WO1993015201A1 (fr)	1993-08-05	Nouvelles tyrosine kinases de proteines
EP1290216A2 (fr)	2003-03-12	Sondes d'acide nucleique a un seul exon derivees du genome humain utiles pour analyser l'expression genique dans des cellules hela humaines ou d'autres cellules epitheliales humaines du col de l'uterus
Sood et al.	2001	Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus
Roebroek et al.	1998	cDNA Cloning, Genomic Organization, and Expression of the HumanRTN2Gene, a Member of a Gene Family Encoding Reticulons
de Conciliis et al.	1998	Characterization ofCxorf5 (71-7A), a novel human cDNA mapping to Xp22 and encoding a protein containing coiled-coil α-helical domains
Albertsen et al.	1996	Sequence, genomic structure, and chromosomal assignment of human DOC-2
Takahashi et al.	1997	Localization of the gene coding for myosin phosphatase, target subunit 1 (MYPT1) to human chromosome 12q15–q21
Couch et al.	1996	Generation of an Integrated Transcription Map of theBRCA2Region on Chromosome 13q12–q13
Derry et al.	1995	The mouse homolog of the Wiskott–Aldrich syndrome protein (WASP) gene is highly conserved and maps near the scurfy (sf) mutation on the X chromosome
Zhao et al.	1996	Characterization and genomic mapping of genes and pseudogenes of a new human protein tyrosine phosphatase
Takenoshita et al.	1996	The genomic structure of the gene encoding the human transforming growth factor β type II receptor (TGF-β RII)
WO2001083739A2 (fr)	2001-11-08	Polypeptides pellino humains
Futamura et al.	1999	Molecular cloning, mapping, and characterization of a novel human gene, MTA1-L1, showing homology to a metastasis-associated gene, MTA1
Jurecic et al.	1998	Identification and cloning of differentially expressed genes by long-distance differential display
US20030165864A1 (en)	2003-09-04	Genes regulated by DNA methylation in tumor cells
JP2002513276A (ja)	2002-05-08	Ｓ―アデノシル―ｌ―ホモシステイン加水分解酵素（ａｈｃｙ）型活性を有する酵素
Baens et al.	1995	Isolation and regional assignment of human chromosome 12p cDNAs